(Q36670892)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

review article

1 reference

title

Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

main subject

cystic fibrosis

0 references

multiple drug resistance

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Valerie Waters

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

22 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

807-819

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Aminoglycoside resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Antimicrobial activity of fosfomycin in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

The clinical use of colistin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Regulation of polymyxin resistance and adaptation to low-Mg2+ environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Bronchoconstriction following nebulised colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Eradication of early Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Update on the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Quorum sensing in the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pseudomonas cepacia infection in cystic fibrosis: an emerging problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

The multifarious, multireplicon Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

An epidemic Burkholderia cepacia complex strain identified in soil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Overexpression of the multidrug efflux pump SmeDEF impairs Stenotrophomonas maltophilia physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Bacterial and host factors implicated in nasal carriage of methicillin-resistant Staphylococcus aureus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Risk factors for methicillin-resistant Staphylococcus aureus carriage in residents of German nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Microbiology of sputum from patients at cystic fibrosis centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

To the editor: Alcaligenes as a pathogen in airways chronic infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Alcaligenes infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Use of amplified ribosomal DNA restriction analysis for identification of Ralstonia and Pandoraea species: interest in determination of the respiratory bacterial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Infection control in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Isolation of infectious cystic fibrosis patients: results of a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

Infection withBurkholderia cepaciaComplex Genomovars in Patients with Cystic Fibrosis: Virulent Transmissible Strains of Genomovar III Can ReplaceBurkholderia multivorans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.807

21 January 2018

Identifiers

DOI

10.1586/14787210.4.5.807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17140357%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference